Por: MarketWatch Business September 25, 2023
But the study, which was conducted by a team of mostly U.K.-based academics, found that in some patients, molnupiravir did not succeed in killing the virus but instead allowed the mutated virus to spread. “Using a systematic approach, we find that a specific class of long phylogenetic branches, distinguished by a high proportion of G-to-A and C-to-T mutations, appear almost exclusively in sequences from 2022, after the introduction of... + full article
Newsweek USA Health September 22, 2023
Since the emergence of SARS-CoV-2 in 2019, the virus has accrued a variety of mutations to infect its human hosts more effectively. Certain antiviral treatments work by increasing the rate of these random mutations, leading some to worry that these drugs could accelerate the... + más
Scientists discover 100,000 viruses never seen before | Newsweek
UFC 292 ceremonial faceoffs: Best photos from Boston | Bleacher Report
Los Angeles Times USA Business June 15, 2023
No one really expected the pharmaceutical industry to lie down and take it when Congress authorized Medicare to start negotiating prices of the prescription drugs it buys for enrollees. By that standard, the federal lawsuit filed June 6 by the big drug manufacturer Merck falls... + más
Healthy Mayfield 'rolling with the punches' as QB2 | ESPN
Did Martha Washington really name a cat after Alexander Hamilton? | The Boston Globe
Portland Press Herald USA World June 06, 2023
This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. AP Photo/Seth Wenig, File Merck is suing the U.S. over a law that will allow the government to negotiate prescription-drug prices with pharmaceutical companies — a reform aimed at cutting costs... + más
Merck Tops Quarterly Profit Estimates but Sees Weaker 2023 Revenue on Lagevrio Sales Drop | MarketWatch
European committee: Regulators should deny Merck's Lagevrio | Associated Press
Associated Press USA Business April 27, 2023
Merck beat first-quarter expectations and hiked its 2023 forecast even as sales plunged for its COVID-19 treatment and a strong dollar hurt revenue. Soaring sales of the drugmaker’s top seller, the cancer treatment Keytruda, helped counter those hits, a drop expected by... + más
Merck has strong quarter even as COVID-19 treatment tumble | ABC News
ABC News USA Business April 27, 2023
Merck has strong quarter even as COVID-19 treatment tumble | Associated Press
Associated Press USA Health February 24, 2023
A European medical committee recommends rejection of Merck’s COVID-19 treatment, Lagevrio, casting fresh doubt on a pill that also stirs concern among U.S. regulators.A European Medicines Agency committee says marketing authorization for the antiviral pill for use in the... + más
Moderna, Merck announce progress in vaccine against skin cancer to significantly boost survival rate | ABC7
MarketWatch USA Business February 02, 2023
The company is expecting revenue to drop in 2023 amid a decline in sales of Lagevrio, its Covid-19 antiviral, and on Thursday set earnings guidance that was well below Wall Street expectations. Still, Merck Chief Financial Officer Caroline Litchfield said that the company’s... + más
Merck, Moderna detail potential skin cancer vaccine progress | WPLG Local 10
Merck, Moderna detail potential skin cancer vaccine progress | ABC News
About iurex | Privacy Policy | Disclaimer |